Fig. 1 · Structure
Documents & Downloads
Virodhamine TFA
Endocannabinoid
Virodhamine TFA is an endocannabinoid that targets cannabinoid (CB) receptors, acting as an antagonist of the CB1 receptor while functioning as an agonist for the CB2 receptor. This compound induces megakaryocytic differentiation through the activation of MAPK signaling pathways and the production of reactive oxygen species (ROS). Virodhamine TFA is valuable for research related to neurological disorders, including Alzheimer's and Parkinson's diseases, offering insights into the modulation of neurotransmission and cellular differentiation.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Antagonist |
| CAS Number | 1415264-56-0 |
| Applications | Endocannabinoid |
| Formula | C24H38F3NO4 |
| Molecular Weight | 461.56 |
| SMILES | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(OCCN)=O.OC(C(F)(F)F)=O |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.